Marina Konopleva, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Redona
    Topic:
    Consulting
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Sanofi Aventis
    Topic:
    Consulting
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Sanofi Aventis
    Topic:
    Research/clinical trials
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Sellas
    Topic:
    Consulting
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Stemline Therapeutics
    Topic:
    Consulting
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Stemline Therapeutics
    Topic:
    Research/clinical trials
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Stemline Therapeutics
    Topic:
    Advisory Board
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Vincerx
    Topic:
    Consulting
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Vincerx
    Topic:
    Advisory Board
    Date added:
    04/22/2024
    Date updated:
    04/22/2024

Pages

Return to 2024 Summit on Hematological Cancers